CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CBAY · as of Jun 8, 2026
Key Statistics
Explore CymaBay Therapeutics, Inc. Data
cbay stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 23 · Buy rate: 47.8%
Competitors & Peers
cbay competitorsCBAY
ALPN
KDNY
LBPH
MOR
MORFStock Performance
Full HistoryAbout CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses.…
what is cymabay therapeutics, inc. · cbay stock overview · cymabay therapeutics, inc. company profile · who is cymabay therapeutics, inc. ceo · cbay NASDAQ · cymabay therapeutics, inc. headquarters · cymabay therapeutics, inc. business segments
About Stock Overview & Key Data
CymaBay Therapeutics, Inc. (CBAY) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 3, 2014. As of the latest trading session, CBAY stock price is $32.48, with a market capitalization of $3.7B. The stock has returned +215.95% over the past 12 months and +36.99% year-to-date.
According to 23 Wall Street analysts, the consensus rating for CymaBay Therapeutics, Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2023, CymaBay Therapeutics, Inc. reported revenue of $31.1M and net income of -$105.4M. For detailed data — including CymaBay Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, CymaBay Therapeutics, Inc. (CBAY) stock price is $32.48. The stock is traded on NASDAQ under the ticker symbol CBAY. The 52-week range is $7.26 – $32.50.